DOMH Profile
Dominari Holdings Inc., a biotechnology firm, is dedicated to advancing small-molecule therapeutics aimed at combating various cancers and viral infections. Founded in 1967 and headquartered in New York, the company is focused on developing innovative treatments for prostate cancer, pancreatic cancer, acute myeloid leukemia (AML), and acute lymphoblastic leukemia (ALL). Dominari's research pipeline includes promising candidates such as DHA-dFdC, a targeted drug for pancreatic cancer, and KPC34, a small-molecule therapy designed to treat AML and ALL.
The company is also making significant strides in antiviral research, developing a platform designed to inhibit the replication of a range of viruses. This includes well-known pathogens such as influenza, Ebola, Marburg virus, as well as coronaviruses like SARS-CoV, MERS-CoV, and SARS-CoV-2. This broad-spectrum antiviral approach reflects Dominari's commitment to addressing both oncological and infectious disease challenges.
Dominari Holdings Inc. maintains strategic partnerships through licensing agreements with prestigious institutions such as the University of Texas, University of Maryland Baltimore, Silo Pharma Inc., and Wake Forest University Health Sciences. These collaborations enhance its research capabilities and facilitate the development of its therapeutics across various domains.
Formerly known as AIkido Pharma Inc., Dominari Holdings Inc. underwent a rebranding in December 2022 to better align with its expanded focus and innovative research objectives. The company's ongoing efforts in biotechnology aim to deliver breakthrough treatments and contribute to advancements in medical science, positioning it as a key player in the field of therapeutic development.
|
